Systematically understanding the immunity leading to CRPC progression.
Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of cancer-related death in American men. Androgen deprivation therapy (ADT) has become a standard treatment strategy for advanced PCa. Although a majority of patients initially respond to ADT well, most of t...
Main Authors: | Zhiwei Ji, Weiling Zhao, Hui-Kuan Lin, Xiaobo Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-09-01
|
Series: | PLoS Computational Biology |
Online Access: | https://doi.org/10.1371/journal.pcbi.1007344 |
Similar Items
-
Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
by: H. Taghizadeh, et al.
Published: (2019-11-01) -
Management of elderly mCRPC patients
by: Seiichiro Ozono
Published: (2015-12-01) -
Withdrawal syndrome and PSA flare in the management of mCRPC with abiraterone
by: Po Hui Chiang
Published: (2015-12-01) -
Use of biomarkers in CRPC and future treatment in Asia
by: Paul Mainwaring
Published: (2015-12-01) -
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients With mCRPC Treated With Abiraterone
by: Cristian Lolli, et al.
Published: (2016-10-01)